ASCOT-BPLA
The Lancet (2005)
Amlodipine-based regimen reduced total CV events by 16% and mortality by 11% vs atenolol-based regimen in 19,257 patients.
Amlodipine
Oral tablet (10mg)Available in all 50 statesMarketing purposes only. Actual medications, if prescribed, are dispensed by a licensed pharmacy.
heart
Long-acting dihydropyridine CCB with 35 to 50 hour half-life. Excellent 24-hour BP control, safe in heart failure, anti-anginal, and metabolically neutral. One of the best-tolerated antihypertensives available.
Excellent 24-hour coverage
Safe in heart failure
Anti-atherosclerotic (CAMELOT)
Metabolically neutral
No commitment · HSA/FSA eligibleNo commitment · HSA/FSA eligible
How it works
Blocks L-type voltage-gated calcium channels in vascular smooth muscle, producing arterial vasodilation. Gradual onset and long half-life avoid reflex tachycardia.
Every Marek client receives this baseline panel before a provider review. Your provider may add additional biomarkers based on your health history, symptoms, and goals, pulling from 1,000+ available markers. See more biomarkers →
Sex hormones
Adrenals & neurosteroids
Growth hormone / IGF-1
Thyroid hormones
Cardiovascular health
Insulin sensitivity
Liver & pancreas
Kidney function
Comprehensive Metabolic Panel (CMP)
Prostate health
Vitamins & minerals
Iron status
Complete Blood Count (CBC)
Clinical evidence
The Lancet (2005)
Amlodipine-based regimen reduced total CV events by 16% and mortality by 11% vs atenolol-based regimen in 19,257 patients.
Safety profile
FAQ
Long-acting dihydropyridine CCB with 35 to 50 hour half-life. Excellent 24-hour BP control, safe in heart failure, anti-anginal, and metabolically neutral. One of the best-tolerated antihypertensives available.
Treatments are dependent on licensed clinical prescription. Client costs vary based on individual labs and panel in treatments and services.